<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Packer, Milton</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PARADIGM-HF: Rationale and Design</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">The Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure and Reduced Ejection Fraction [PARADIGM-HF; NCT01035255] is the largest trial ever conducted with patients with heart failure with a reduced left ventricular ejection fraction and was designed to replace the current standard of care. This article discusses the rationale and design of the PARADIGM-HF trial.</style></abstract><number><style face="normal" font="default" size="100%">12</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>